<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
<journal-title>Journal of International Medical Research</journal-title>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300060513477264</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060513477264</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Recipient IL-6-572C/G genotype is associated with reduced incidence of acute rejection following liver transplantation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Yao</surname><given-names>Jia</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513477264">1</xref>
<xref ref-type="aff" rid="aff2-0300060513477264">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Feng</surname><given-names>Xiao-Wen</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513477264">1</xref>
<xref ref-type="aff" rid="aff2-0300060513477264">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yu</surname><given-names>Xiao-Bo</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513477264">1</xref>
<xref ref-type="aff" rid="aff2-0300060513477264">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xie</surname><given-names>Hai-Yang</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513477264">1</xref>
<xref ref-type="aff" rid="aff2-0300060513477264">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhu</surname><given-names>Li-Xian</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513477264">1</xref>
<xref ref-type="aff" rid="aff2-0300060513477264">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yang</surname><given-names>Zhe</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513477264">1</xref>
<xref ref-type="aff" rid="aff2-0300060513477264">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wei</surname><given-names>Ba-Jin</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513477264">1</xref>
<xref ref-type="aff" rid="aff2-0300060513477264">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zheng</surname><given-names>Shu-Sen</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513477264">1</xref>
<xref ref-type="aff" rid="aff2-0300060513477264">2</xref>
<xref ref-type="corresp" rid="corresp1-0300060513477264"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhou</surname><given-names>Lin</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513477264">1</xref>
<xref ref-type="aff" rid="aff2-0300060513477264">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0300060513477264"><label>1</label>Division of Hepatobiliary and Pancreatic Surgery and Department of Surgery First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China</aff>
<aff id="aff2-0300060513477264"><label>2</label>Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Key Laboratory of Organ Transplantation, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China</aff>
<author-notes>
<fn fn-type="other" id="fn1-0300060513477264"><p>These data were presented as an oral presentation at the 14th International Symposium on Viral Hepatitis and Liver Disease, Shanghai International Convention Centre, Shanghai, China, 25 June 2012: Abstract number: OP-062.</p></fn>
<corresp id="corresp1-0300060513477264">Dr Shu-Sen Zheng and Dr Lin Zhou, Key Laboratory of Organ Transplantation, 79 Qing Chun Road, Hangzhou, Zhejiang Province, 310003, China. E-mails: <email>shusenzheng@zju.edu.cn</email>; <email>linzhou19@163.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>2</issue>
<fpage>356</fpage>
<lpage>364</lpage>
<history>
<date date-type="received"><day>29</day><month>8</month><year>2012</year></date>
<date date-type="accepted"><day>10</day><month>12</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec16-0300060513477264"><title>Objective</title>
<p>Acute rejection resulting from alloimmune responses is a major risk factor affecting patient survival following liver transplantation. Since interleukin (IL)-6 can mediate acute rejection, the association between IL-6 gene single nucleotide polymorphisms (SNPs) and incidence of acute rejection in liver transplant recipients was investigated.</p>
</sec>
<sec id="sec17-0300060513477264"><title>Methods</title>
<p>Patients who received liver transplant between January 2005 and December 2010 were typed for <italic>IL6</italic>-572C/G (rs1800796) polymorphisms using the snapshot technique. Association between genotype and acute rejection was analysed using the SNP Statistics website: <ext-link ext-link-type="uri" xlink:href="http://bioinfo.iconcologia.net/snpstats/start.htm">http://bioinfo.iconcologia.net/snpstats/start.htm</ext-link>. Allelic and genotypic distributions for rs1800796 were compared among 335 patients with or without acute rejection within the first 6 months following liver transplant.</p>
</sec>
<sec id="sec18-0300060513477264"><title>Results</title>
<p>Incidence of acute rejection was 11.94%. A heterozygous CG genotype for <italic>IL6</italic>-572C/G was associated with a lower acute rejection rate compared with homozygous CC or GG genotypes.</p>
</sec>
<sec id="sec19-0300060513477264"><title>Conclusion</title>
<p><italic>IL6</italic>-572 CG genotype may be related to protection from acute rejection following liver transplant in Han Chinese patients.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Acute rejection</kwd>
<kwd>interleukin-6 (IL-6)</kwd>
<kwd><italic>IL6</italic>-572C/G</kwd>
<kwd>liver transplantation</kwd>
<kwd>rs1800796</kwd>
<kwd>single nucleotide polymorphism (SNP)</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060513477264" sec-type="intro"><title>Introduction</title>
<p>Liver transplantation is regarded to be an effective therapeutic option for patients with end-stage liver disease due to improvements in surgical techniques and postoperative management, and the introduction of new immunosuppressive agents and protocols.<sup><xref ref-type="bibr" rid="bibr1-0300060513477264">1</xref></sup> Survival rates following liver transplantation are continually improving, with 1-year graft survival rates exceeding 80%. Graft failure occurs in up to 15% of patients during the first year, however, rising to 25% within 5 years following transplant.<sup><xref ref-type="bibr" rid="bibr2-0300060513477264">2</xref>,<xref ref-type="bibr" rid="bibr3-0300060513477264">3</xref></sup> Acute rejection may result in graft loss, increased risk of chronic graft dysfunction, and suboptimal long-term outcome.<sup><xref ref-type="bibr" rid="bibr4-0300060513477264">4</xref></sup> Despite improvements in immunosuppressive therapy, 20–40% of patients still have one or more acute rejection episodes.<sup><xref ref-type="bibr" rid="bibr5-0300060513477264">5</xref></sup></p>
<p>There is accumulating evidence to suggest that cytokines play a central role in the immunological events that occur following transplantation, and are intimately linked to graft rejection. For example, T-helper subtype 1 cytokines including interleukin (IL)-2, IL-15 and tumour necrosis factor (TNF)-α are associated with graft rejection, and T-helper subtype 2 cytokines such as IL-10 are associated with graft tolerance.<sup><xref ref-type="bibr" rid="bibr6-0300060513477264">6</xref><xref ref-type="bibr" rid="bibr7-0300060513477264"/><xref ref-type="bibr" rid="bibr8-0300060513477264"/><xref ref-type="bibr" rid="bibr9-0300060513477264"/>–<xref ref-type="bibr" rid="bibr10-0300060513477264">10</xref></sup> Polymorphisms with functional significance in the promoter and coding regions of cytokine genes have been suggested as possible factors in graft rejection. The polymorphisms of <italic>TNFA</italic>-308 G/A, <italic>IL10</italic>-1082 G/A, <italic>IL6</italic>-174 G/C and interferon-γ (<italic>IFNG</italic>) +874 T/A have all been reported to be associated with acute rejection.<sup><xref ref-type="bibr" rid="bibr11-0300060513477264">11</xref><xref ref-type="bibr" rid="bibr12-0300060513477264"/>–<xref ref-type="bibr" rid="bibr13-0300060513477264">13</xref></sup></p>
<p>The multifunctional cytokine IL-6 provokes a broad range of cellular and physiological responses, including the development of the nervous and haematopoietic systems, acute-phase responses, inflammatory and immune responses through regulation of gene activation, cell growth, proliferation, survival, and differentiation.<sup><xref ref-type="bibr" rid="bibr14-0300060513477264">14</xref></sup> Polymorphisms in the promoter region of the IL-6 gene may result in variations in transcription and expression between individuals. Genetic variants could, therefore, influence an individual’s susceptibility to a diverse range of diseases. Several studies have identified IL-6 to be associated with acute allograft rejection in patients<sup><xref ref-type="bibr" rid="bibr13-0300060513477264">13</xref></sup> and in experimental models.<sup><xref ref-type="bibr" rid="bibr15-0300060513477264">15</xref></sup> It has been reported that <italic>IL6</italic>-174 G/C polymorphisms have predictive values for acute rejection following liver transplantation,<sup><xref ref-type="bibr" rid="bibr16-0300060513477264">16</xref></sup> however, there are no published studies on the influence of IL-6 promoter single nucleotide polymorphisms (SNPs) on acute rejection following liver transplantation in China.</p>
<p>The present study investigated the association between IL-6 gene single nucleotide polymorphisms (SNPs) and incidence of acute rejection in liver transplant recipients.</p>
</sec>
<sec id="sec2-0300060513477264" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0300060513477264"><title>Study Population</title>
<p>Consecutive patients who received liver transplants at the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, between January 2005 and December 2010, were enrolled. Patient characteristics and clinical data were retrospectively derived from medical records, or extracted from an electronic database that is prospectively maintained. All patients were Han Chinese. The inclusion criteria for the study were availability of adequate sample and patient survival &gt;6 months after liver transplantation. All patients were followed up for ≥6 months.</p>
<p>This study was approved by the Ethical Review Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; written informed consent was obtained from all patients.</p>
</sec>
<sec id="sec4-0300060513477264"><title>Immunosuppressant Regimen and Rejection Diagnosis</title>
<p>The routine immunosuppressant regimen comprised 1–2 mg/day tacrolimus, together with either 1 mg/day rapamycin or 500 mg/day mycophenolate mofetil, and 120 mg prednisone q12h; all drugs were administered orally.</p>
<p>Acute rejection diagnosis was based on conventional clinical parameters (fever and elevation of bilirubin and/or transaminase levels in the absence of vascular or biliary problems) and biopsy findings, according to Banff criteria.<sup><xref ref-type="bibr" rid="bibr17-0300060513477264">17</xref></sup> Acute rejection episodes were managed with high doses (500 mg) of methylprednisolone, administered orally for 3 days.</p>
<p>Patients who suffered acute rejection within 6 months following transplantation were classified into the acute rejection (AR) group. All other patients were classified into the nonacute rejection (NAR) group.</p>
</sec>
<sec id="sec5-0300060513477264"><title>DNA Extraction</title>
<p>Venous whole blood was collected using commercial collection tubes containing ethylenediaminetetra-acetic acid (REF367841; BD Biosciences, San Jose, CA, USA) and stored at −80°C before isolation of genomic DNA.</p>
<p>Genomic DNA was isolated from 500 µl of blood using a Maxwell® 16 Blood DNA Purification kit (Promega, Madison, WI, USA), according to the manufacturer’s instructions. DNA was stored in elution buffer at −80°C until analysis of cytokine genotypes by polymerase chain reaction (PCR).</p>
</sec>
<sec id="sec6-0300060513477264"><title>Polymorphism Genotyping</title>
<p>Details of <italic>IL6</italic> promoter region SNPs for the Chinese population of Beijing were searched for in the public genotyping database <ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org">http://www.hapmap.org</ext-link>. The search criteria included a minor allele frequency ≥20% and <italic>r</italic><sup>2</sup> ≥0.8. The current study focused on <italic>IL6-</italic>572 C/G (rs1800796), and SNPs at loci <italic>IL6</italic>-572 C/G were detected by DNA sequencing.</p>
<p>The fragment was first amplified by PCR. Allele-specific forward primers and generic reverse primers were designed using the <italic>IL6</italic> gene sequence published in the nucleotide database at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</ext-link>. The primer pairs for this multiplex PCR were the following: forward, 5′-TGGGCTGAAGCAGGTGAAGA-3′; reverse, 5′-GCTGAAGTCATGCACGAAGTTTTACA-3′. The PCR reaction system included 1 × HotStarTaq® buffer (QIAGEN GmbH, Hilden, Germany), 3.0 mM Mg<sup>2+</sup>, 0.3 mM dNTP, 0.1 µM of each primer, 1 U HotstarTaq® polymerase (QIAGEN GmbH), and 5–10 ng genomic DNA, in a total volume of 20 µl. The cycling programme was carried out using an Applied Biosystems® 2720 Thermal Cycler (Applied Biosystems, Foster City, CA, USA) as follows: denaturation at 95°C for 15 min followed by 12 cycles of 94°C for 20 s, 65°C (reduced by 0.5°C per cycle) for 40 s and 72°C for 100 s, then 23 cycles of 94°C for 20 s, 57°C for 30 s and 72°C for 90 s, with a final extension at 72°C for 2 min. Ultrapure water was used as a negative control. The PCR products were separated on 1–2% agarose gels and visualized using ethidium bromide staining and ultraviolet light.</p>
<p>A mixture containing 1 U of shrimp alkaline phosphatase (Promega) and 6 U of exonuclease I was used to purify 10 µl of PCR product. The mixture was incubated at 37°C for 60 min followed by inactivation at 75°C for 15 min. Then, 2 µl of purified PCR product was mixed with 5 µl SNaPshot® Multiplex kit (Applied Biosystems), 2 µl ultrapure water, and 1 µl sequencing primer for further reaction. The sequencing primer was: 5′-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTTCTGGCTCTCCCTGTGAG-3′. The cycling programme was as follows: denaturation at 96°C for 1 min followed by 28 cycles of 96°C for 10 s, 50°C for 5 s, 60°C for 30 s, then a final extension at 72°C for 2 min. Next, 1 U of shrimp alkaline phosphatase was mixed with 10 µl of PCR product, incubated at 37°C for 60 min and inactivated at 75°C for 15 min for purification. Next, 0.5 µl of the purified PCR product was mixed with 0.5 µl Genescan™ –120 LIZ® size standard and 9 µl HiDi™ (Applied Biosystems). Denaturing of extension products was performed at 95°C for 5 min and the mixture was sequenced using an ABI 3130xl Genetic Analyser (Applied Biosystems). Sequence data were analysed using Gene Mapper® software, version 4.0 (Applied Biosystems).</p>
</sec>
<sec id="sec7-0300060513477264"><title>Statistical Analyses</title>
<p>Statistical analyses were performed using the SPSS® software package, version 16.0 (SPSS Inc., Chicago, IL, USA) for windows®. Between-group differences in clinical characteristics and the frequencies of alleles in patients with or without acute rejection were compared using Pearson’s χ<sup>2</sup>-test, with Yates’ correction for continuity (or Fisher’s exact test where appropriate). Genotypes were analysed using the website for SNP Statistics: <ext-link ext-link-type="uri" xlink:href="http://bioinfo.iconcologia.net/snpstats/start.htm">http://bioinfo.iconcologia.net/snpstats/start.htm</ext-link>. Multivariate logistic regression analysis was used to analyse the association of genotypes in four inheritance models (codominant, dominant, recessive, overdominant) in the AR and NAR groups. All tests were two-tailed and <italic>P</italic> values ≤0.05 were considered to be statistically significant.</p>
</sec>
</sec>
<sec id="sec8-0300060513477264" sec-type="results"><title>Results</title>
<p>A total of 335 patients were included in this study: 290 males and 45 females, with a mean ± SD age at transplantation of 46.6 ± 9.9 years. Patients were classified into two groups: 295 (88.06%) into the NAR group and 40 (11.94%) into the AR group. The mean ± SD time of acute rejection onset was 46.2 ± 42.1 days. The primary indications for liver transplantation included hepatocellular carcinoma, alcoholic cirrhosis and primary biliary hepatitis. No significant between-group differences were found regarding sex, blood type, model for end-stage liver disease (MELD) score<sup><xref ref-type="bibr" rid="bibr18-0300060513477264">18</xref></sup> and primary disease relating to the need for liver transplantation (<xref ref-type="table" rid="table1-0300060513477264">Table 1</xref>).
<table-wrap id="table1-0300060513477264" position="float"><label>Table 1.</label><caption><p>Baseline characteristics and primary pre-liver transplant disease for 335 patients assigned to an acute rejection (AR) group or nonacute rejection (NAR) group following liver transplantatio.</p></caption>
<graphic alternate-form-of="table1-0300060513477264" xlink:href="10.1177_0300060513477264-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Characteristic</th>
<th colspan="2">Patient group<hr/></th>
<th rowspan="2">Statistical significance<sup><xref ref-type="table-fn" rid="table-fn2-0300060513477264">a</xref></sup></th>
</tr>
<tr><th>AR <italic>n</italic> = 40</th>
<th>NAR <italic>n</italic> = 295</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Age range, years</td>
<td>31–71</td>
<td>13–66</td>
<td>NA</td>
</tr>
<tr>
<td>Survival time, days</td>
<td>775.9 ± 726.0</td>
<td>1093.8 ± 638.8</td>
<td>NA</td>
</tr>
<tr>
<td>Sex</td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> Male</td>
<td>36 (90.0)</td>
<td>254 (86.1)</td>
<td/>
</tr>
<tr>
<td> Female</td>
<td>4 (10.0)</td>
<td>41 (13.9)</td>
<td/>
</tr>
<tr>
<td>Blood type</td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> A</td>
<td>9 (22.5)</td>
<td>89 (30.2)</td>
<td/>
</tr>
<tr>
<td> B</td>
<td>13 (32.5)</td>
<td>80 (27.1)</td>
<td/>
</tr>
<tr>
<td> AB</td>
<td>3 (7.5)</td>
<td>26 (8.8)</td>
<td/>
</tr>
<tr>
<td> O</td>
<td>15 (37.5)</td>
<td>100 (33.9)</td>
<td/>
</tr>
<tr>
<td>MELD score<sup><xref ref-type="bibr" rid="bibr18-0300060513477264">18</xref></sup></td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> &lt;10</td>
<td>10 (25.0)</td>
<td>48 (16.3)</td>
<td/>
</tr>
<tr>
<td> 10–19</td>
<td>12 (30.0)</td>
<td>115 (39.0)</td>
<td/>
</tr>
<tr>
<td> 20–29</td>
<td>10 (25.0)</td>
<td>94 (31.9)</td>
<td/>
</tr>
<tr>
<td> ≥30</td>
<td>8 (20.0)</td>
<td>38 (12.9)</td>
<td/>
</tr>
<tr>
<td>Pre-liver transplant disease</td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> Hepatocellular carcinoma</td>
<td>16 (40.0)</td>
<td>109 (36.9)</td>
<td/>
</tr>
<tr>
<td> Fulminant hepatitis</td>
<td>11 (27.5)</td>
<td>46 (15.6)</td>
<td/>
</tr>
<tr>
<td> Decompensated liver cirrhosis</td>
<td>13 (32.5)</td>
<td>134 (45.4)</td>
<td/>
</tr>
<tr>
<td> Other</td>
<td>0 (0.0)</td>
<td>6 (2.0)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0300060513477264"><p>Data expressed as mean or <italic>n</italic> (%) of patients.</p></fn>
<fn id="table-fn2-0300060513477264"><label>a</label><p>Pearson’s χ<sup>2</sup>-test with Yates’ correction for continuity (or Fisher’s exact test).</p></fn>
<fn id="table-fn3-0300060513477264"><p>MELD, model for end-stage liver disease; NA, not applicable; NS, no statistically significant between-group differences (<italic>P</italic> &gt; 0.05).</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Liver transplant patients were genotyped for <italic>IL6</italic>-572 C/G (rs1800796), which met the search criteria of minor allele frequency ≥20% and <italic>r</italic><sup>2</sup> ≥0.8. There was no significant difference in rs1800796 allele frequency between the AR and NAR groups (<xref ref-type="table" rid="table2-0300060513477264">Table 2</xref>).
<table-wrap id="table2-0300060513477264" position="float"><label>Table 2.</label><caption><p>Distribution of genotypes and allele frequency for IL-6-572 C/G (rs1800796) in 335 patients assigned to an acute rejection (AR) group or nonacute rejection (NAR) group following liver transplantatio.</p></caption>
<graphic alternate-form-of="table2-0300060513477264" xlink:href="10.1177_0300060513477264-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">IL-6 -572C/G characteristic</th>
<th colspan="2">Patient group<hr/></th>
<th rowspan="2">OR (95% CI)</th>
<th rowspan="2">Statistical significance</th>
<th rowspan="2">Model</th>
</tr>
<tr><th>AR <italic>n</italic> = 40</th>
<th>NAR <italic>n</italic> = 295</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Allele</td>
<td/>
<td/>
<td>—</td>
<td>NS<sup><xref ref-type="table-fn" rid="table-fn5-0300060513477264">a</xref></sup></td>
<td>—</td>
</tr>
<tr>
<td> C</td>
<td>63 (78.75)</td>
<td>444 (75.25)</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> G</td>
<td>17 (21.25)</td>
<td>146 (24.75)</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Genotype</td>
<td/>
<td/>
<td/>
<td>NS<sup>c</sup></td>
<td>Codominant</td>
</tr>
<tr>
<td> CC</td>
<td>27 (67.5)</td>
<td>164 (55.6)</td>
<td>1.00</td>
<td/>
<td/>
</tr>
<tr>
<td> CG</td>
<td>9 (22.5)</td>
<td>116 (39.3)</td>
<td>0.47 (0.21, 1.04)</td>
<td/>
<td/>
</tr>
<tr>
<td> GG</td>
<td>4 (10)</td>
<td>15 (5.1)</td>
<td>1.62 (0.50, 5.25)</td>
<td/>
<td/>
</tr>
<tr>
<td> CC vs</td>
<td>27 (67.5)</td>
<td>164 (55.6)</td>
<td>1.00</td>
<td>NS<sup><xref ref-type="table-fn" rid="table-fn6-0300060513477264">b</xref></sup></td>
<td>Dominant</td>
</tr>
<tr>
<td> CG + GG</td>
<td>13 (32.5)</td>
<td>131 (44.4)</td>
<td>0.60 (0.30, 1.21)</td>
<td/>
<td/>
</tr>
<tr>
<td> CC + CG vs</td>
<td>36 (90.0)</td>
<td>280 (94.9)</td>
<td>1.00</td>
<td>NS<sup><xref ref-type="table-fn" rid="table-fn6-0300060513477264">b</xref></sup></td>
<td>Recessive</td>
</tr>
<tr>
<td> GG</td>
<td>4 (10.0)</td>
<td>15 (5.1)</td>
<td>2.07(0.65, 6.59)</td>
<td/>
<td/>
</tr>
<tr>
<td> CC + GG vs</td>
<td>31 (77.5)</td>
<td>179 (60.7)</td>
<td>1.00</td>
<td><italic>P</italic> = 0.033<sup><xref ref-type="table-fn" rid="table-fn6-0300060513477264">b</xref></sup></td>
<td>Overdominant</td>
</tr>
<tr>
<td> CG</td>
<td>9 (22.5)</td>
<td>116 (39.3)</td>
<td>0.45 (0.21, 0.98)</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0300060513477264"><p>Data presented as within-group <italic>n</italic> (%) incidence.</p></fn>
<fn id="table-fn5-0300060513477264"><label>a</label><p>Pearson’s χ<sup>2</sup>-test with Yates’ correction for continuity.</p></fn>
<fn id="table-fn6-0300060513477264"><label>b</label><p>Genotypes analysed using multivariate logistic regression analysis, using the website for SNP Statistics: <ext-link ext-link-type="uri" xlink:href="http://bioinfo.iconcologia.net/snpstats/start.htm">http://bioinfo.iconcologia.net/snpstats/start.htm</ext-link>.</p></fn>
<fn id="table-fn7-0300060513477264"><p>OR, odds ratio; CI, confidence intervals; NS, no statistically significant between-group differences (<italic>P</italic> &gt; 0.05); vs, versus.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Analysis of genotype distribution, to assess whether there was an association between genotype and acute rejection, is shown in <xref ref-type="table" rid="table2-0300060513477264">Table 2</xref></p>
<p>Multivariate logistic regression analysis of the association of genotypes in four inheritance models showed that, in the overdominant model, the heterozygous CG genotype was associated with a significantly decreased acute rejection rate when compared with the homozygous CC and GG genotypes (<italic>P</italic> = 0.033) (<xref ref-type="table" rid="table2-0300060513477264">Table 2</xref>).</p>
</sec>
<sec id="sec9-0300060513477264" sec-type="discussion"><title>Discussion</title>
<p>Studies have focused on the identification of individual immune response characteristics following liver transplantation, in an attempt to predict acute rejection and adapt immunosuppressive therapy accordingly.<sup><xref ref-type="bibr" rid="bibr11-0300060513477264">11</xref>,<xref ref-type="bibr" rid="bibr19-0300060513477264">19</xref></sup> The current study investigated <italic>IL6</italic>-572 C/G in liver transplant recipients, and examined whether polymorphisms in the <italic>IL6</italic> promoter region had a predictive value for acute rejection in these patients. There were no statistically significant between-group differences in the distribution of <italic>IL6</italic>-572 C/G alleles, but the <italic>IL6</italic>-572 CG genotype was strongly associated with a significantly lower rate of acute rejection.</p>
<p>Interleukin-6 is a mediator of the acute-phase response and differentiation or activation of macrophages (and B and T cells), and has both pro- and anti-inflammatory properties.<sup><xref ref-type="bibr" rid="bibr20-0300060513477264">20</xref></sup> Furthermore, IL-6 can activate the signal transducer and activator of transcription 3 and tyrosine-protein phosphatase nonreceptor type 11/growth factor-receptor-bound protein 2-associated binder/mitogen-activated protein kinase signalling pathways, via the glycoprotein 130 signal transducer.<sup><xref ref-type="bibr" rid="bibr21-0300060513477264">21</xref></sup> IL-6 has been associated with various diseases. For example, increased levels of IL-6 are observed in diseases such as rheumatoid arthritis,<sup><xref ref-type="bibr" rid="bibr22-0300060513477264">22</xref></sup> chronic inflammatory proliferative disease, Graves’ disease, and systemic lupus erythematosus.<sup><xref ref-type="bibr" rid="bibr14-0300060513477264">14</xref></sup> High levels of plasma IL-6 have been associated with acute rejection,<sup><xref ref-type="bibr" rid="bibr23-0300060513477264">23</xref></sup> and high levels of IL-6 have been consistently associated with increased graft rejection following liver transplantation.<sup><xref ref-type="bibr" rid="bibr24-0300060513477264">24</xref>,<xref ref-type="bibr" rid="bibr25-0300060513477264">25</xref></sup> Because several lines of evidence support the involvement of IL-6 in various diseases, genetic polymorphisms related to these diseases have been extensively studied. The human <italic>IL6</italic> gene is located on chromosome 7p21. Four polymorphisms, −597 G/A, −572 C/G, −373 A(n)T(n) and −174 G/C, have been identified in the promoter region of the human IL-6 gene. A polymorphism in the 5′ flanking region of the IL-6 gene at position −174 G/C will affect <italic>IL6</italic> gene transcription.<sup><xref ref-type="bibr" rid="bibr26-0300060513477264">26</xref></sup> The polymorphism at position −174 (rs1800795) in the <italic>IL6</italic> promoter region results in a G to C transition, leading to a subsequent decrease in <italic>IL6</italic> expression and plasma levels.<sup><xref ref-type="bibr" rid="bibr26-0300060513477264">26</xref></sup> Following coronary artery bypass surgery, patients with the −174 C/C allele show higher plasma IL-6 levels than patients with the −174 G/G allele.<sup><xref ref-type="bibr" rid="bibr27-0300060513477264">27</xref></sup> Both −174 G/C and −597 G/A in the <italic>IL6</italic> gene have been related to a higher risk of developing type 2 diabetes mellitus.<sup><xref ref-type="bibr" rid="bibr28-0300060513477264">28</xref></sup> Studies on the impact of recipient −174 G/C polymorphism on acute rejection following renal transplantation have provided conflicting results. One study found a lower frequency of G/G or G/C genotype in recipients who developed acute rejection,<sup><xref ref-type="bibr" rid="bibr29-0300060513477264">29</xref></sup> while another found a higher frequency of these genotypes,<sup><xref ref-type="bibr" rid="bibr30-0300060513477264">30</xref>,<xref ref-type="bibr" rid="bibr31-0300060513477264">31</xref></sup> although the results of these studies were not statistically significant. High levels of the G/G and G/C IL-6 promoter genotypes have been shown to be significantly associated with decreased risk of acute rejection following liver transplant.<sup><xref ref-type="bibr" rid="bibr16-0300060513477264">16</xref></sup></p>
<p>Although there is no published research relating <italic>IL6</italic>-597 G/A (rs1800797) polymorphisms and acute rejection, some studies report an association with osteoarthritis.<sup><xref ref-type="bibr" rid="bibr32-0300060513477264">32</xref>,<xref ref-type="bibr" rid="bibr33-0300060513477264">33</xref></sup> Most studies have focused on the <italic>IL6</italic>-174 G/C polymorphism, which has been identified as having an association with acute rejection following liver transplantation.<sup><xref ref-type="bibr" rid="bibr16-0300060513477264">16</xref></sup> Investigations into the <italic>IL6</italic>-572 C/G polymorphism have demonstrated IL-6 levels to be significantly lower in subjects carrying the −572 G allele compared with those carrying the −572 C allele, and the C→G variation was shown to reduce the transcriptional activity of the <italic>IL6</italic> promoter significantly.<sup><xref ref-type="bibr" rid="bibr27-0300060513477264">27</xref>,<xref ref-type="bibr" rid="bibr34-0300060513477264">34</xref></sup> Other research suggests that individuals carrying the GG genotype have a significantly higher risk of chronic periodontitis,<sup><xref ref-type="bibr" rid="bibr35-0300060513477264">35</xref></sup> and the CC genotype may increase the risk for Alzheimer's disease.<sup><xref ref-type="bibr" rid="bibr36-0300060513477264">36</xref></sup> The present study investigated the association between SNPs of the <italic>IL6</italic> promoter region and the incidence of acute rejection in liver transplant recipients. Only the −572 C/G (rs1800796) polymorphism met the criteria of minor allele frequency ≥20% and <italic>r</italic><sup>2</sup> ≥0.8 for the Chinese population of Beijing. Thus, further research focused on <italic>IL6</italic>-572 C/G.</p>
<p>Studies on transcriptional regulation of the <italic>IL6</italic> gene have identified at least four transcription factor sites located within the IL-6 promoter region, including nuclear factor-κB, adenosine 3′5′ cyclic monophosphate response element binding protein, CCAAT-enhancer-binding protein, and activator protein 1.<sup><xref ref-type="bibr" rid="bibr37-0300060513477264">37</xref></sup> Under normal conditions, some transcription factors play a key role, whereas others play a cofactor role. Although research has suggested that subjects carrying the −572 G allele could possess significantly reduced <italic>IL6</italic> promoter transcriptional activity, the role of each binding site and its cognate transcription factor(s) in the regulation of IL-6 expression is complex and dependent on cell type and stimulus.<sup><xref ref-type="bibr" rid="bibr37-0300060513477264">37</xref></sup> The heterozygous CG genotype in <italic>IL6</italic>-572 C/G in the present study appeared to be a protection factor for acute rejection after liver transplantation. With regard to acute rejection of the liver, the CG genotype may reduce the function of the key transcription factor and this co-operative function may reduce the transcriptional activity of the IL-6 promoter, subsequently reducing IL-6 levels. When this variation occurs in both alleles, the genotype for CC or GG, the key transcription factor may lose its function and the cotranscription factor may compensate, resulting in both unchanged IL-6 promoter transcriptional activity and unchanged IL-6 levels. Thus, <italic>IL6</italic>-572 C/G may play a role in modifying the risk of acute rejection.</p>
<p>In conclusion, this is the first report to evaluate the relationship between polymorphisms of <italic>IL6</italic>-572 C/G and acute rejection following liver transplant. The true biological function of IL-6 in acute rejection is still unclear, so further research should focus on the function of the <italic>IL6</italic>-572 C/G SNP. There is a possibility that genotyping could be used as a predictor of acute rejection. This may have significant implications for future immunosuppressive therapy to prevent acute rejection, following liver transplant procedures, in the Han Chinese population.</p>
</sec>
</body>
<back><ack>
<title>Acknowledgements</title>
<p>We thank all patients who participated in this study, and Zhang Lin and Fu Jilei for collecting the clinical data.</p></ack>
<sec id="sec14-0300060513477264"><title>Declaration of Conflicting Interest</title>
<p>The Authors declare that there are no conflicts of interest.</p>
</sec>
<sec id="sec15-0300060513477264"><title>Funding</title>
<p>This work was supported by the National Basic Research Program for Innovative Research Group of China (No.81121002), National Basic Research Program of China (973 Program) (No.2009CB522407), National Hi-tech Project 863 (No.2011AA020103) and the Nonprofit Technology and Application Research Program of Zhejiang Province, grant number 2011C37013.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0300060513477264"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esquivel</surname><given-names>CO</given-names></name></person-group>. <article-title>Liver transplantation: where we are and where we are heading</article-title>. <source>Transplant Proc</source> <year>2010</year>; <volume>42</volume>: <fpage>610</fpage>–<lpage>612</lpage>.</citation></ref>
<ref id="bibr2-0300060513477264"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thuluvath</surname><given-names>PJ</given-names></name><name><surname>Guidinger</surname><given-names>MK</given-names></name><name><surname>Fung</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Liver transplantation in the United States, 1999–2008</article-title>. <source>Am J Transplant</source> <year>2010</year>; <volume>10</volume>: <fpage>1003</fpage>–<lpage>1019</lpage>.</citation></ref>
<ref id="bibr3-0300060513477264"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merion</surname><given-names>RM</given-names></name></person-group>. <article-title>Current status and future of liver transplantation</article-title>. <source>Semin Liver Dis</source> <year>2010</year>; <volume>30</volume>: <fpage>411</fpage>–<lpage>421</lpage>.</citation></ref>
<ref id="bibr4-0300060513477264"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mas</surname><given-names>VR</given-names></name><name><surname>Fisher</surname><given-names>RA</given-names></name><name><surname>Maluf</surname><given-names>DG</given-names></name><etal/></person-group>. <article-title>Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation</article-title>. <source>Clin Genet</source> <year>2004</year>; <volume>65</volume>: <fpage>191</fpage>–<lpage>201</lpage>.</citation></ref>
<ref id="bibr5-0300060513477264"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaked</surname><given-names>A</given-names></name><name><surname>Ghobrial</surname><given-names>RM</given-names></name><name><surname>Merion</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation</article-title>. <source>Am J Transplant</source> <year>2009</year>; <volume>9</volume>: <fpage>301</fpage>–<lpage>308</lpage>.</citation></ref>
<ref id="bibr6-0300060513477264"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imagawa</surname><given-names>DK</given-names></name><name><surname>Millis</surname><given-names>JM</given-names></name><name><surname>Olthoff</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>The role of tumor necrosis factor in allograft rejection. I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation</article-title>. <source>Transplantation</source> <year>1990</year>; <volume>50</volume>: <fpage>219</fpage>–<lpage>225</lpage>.</citation></ref>
<ref id="bibr7-0300060513477264"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dallman</surname><given-names>MJ</given-names></name></person-group>. <article-title>Cytokines as mediators of organ graft rejection and tolerance</article-title>. <source>Curr Opin Immunol</source> <year>1993</year>; <volume>5</volume>: <fpage>788</fpage>–<lpage>793</lpage>.</citation></ref>
<ref id="bibr8-0300060513477264"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>L</given-names></name></person-group>. <article-title>T cell responses: IL-2 overrules tolerogenic liver responses</article-title>. <source>Nat Rev Immunol</source> <year>2010</year>; <volume>10</volume>: <fpage>289</fpage>–<lpage>289</lpage>.</citation></ref>
<ref id="bibr9-0300060513477264"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mottram</surname><given-names>PL</given-names></name><name><surname>Han</surname><given-names>WR</given-names></name><name><surname>Purcell</surname><given-names>LJ</given-names></name><etal/></person-group>. <article-title>Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-gamma in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy</article-title>. <source>Transplantation</source> <year>1995</year>; <volume>59</volume>: <fpage>559</fpage>–<lpage>565</lpage>.</citation></ref>
<ref id="bibr10-0300060513477264"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minguela</surname><given-names>A</given-names></name><name><surname>Torío</surname><given-names>A</given-names></name><name><surname>Marín</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Implication of Th1, Th2, and Th3 cytokines in liver graft acceptance</article-title>. <source>Transplant Proc</source> <year>1999</year>; <volume>31</volume>: <fpage>519</fpage>–<lpage>520</lpage>.</citation></ref>
<ref id="bibr11-0300060513477264"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warlé</surname><given-names>MC</given-names></name><name><surname>Metselaar</surname><given-names>HJ</given-names></name><name><surname>Hop</surname><given-names>WC</given-names></name><etal/></person-group>. <article-title>Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis</article-title>. <source>Liver Transpl</source> <year>2005</year>; <volume>11</volume>: <fpage>19</fpage>–<lpage>26</lpage>.</citation></ref>
<ref id="bibr12-0300060513477264"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>SE</given-names></name><name><surname>Welsh</surname><given-names>KI</given-names></name></person-group>. <article-title>The role of cytokine polymorphisms in rejection after solid organ transplantation</article-title>. <source>Genes Immun</source> <year>2001</year>; <volume>2</volume>: <fpage>297</fpage>–<lpage>303</lpage>.</citation></ref>
<ref id="bibr13-0300060513477264"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Association between IL-6 –174G/C polymorphism and acute rejection of renal allograft: evidence from a meta-analysis</article-title>. <source>Transpl Immunol</source> <year>2012</year>; <volume>26</volume>: <fpage>11</fpage>–<lpage>18</lpage>.</citation></ref>
<ref id="bibr14-0300060513477264"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>T</given-names></name></person-group>. <article-title>Interleukin 6 and its receptor: ten years later</article-title>. <source>Int Rev Immunol</source> <year>1998</year>; <volume>16</volume>: <fpage>249</fpage>–<lpage>284</lpage>.</citation></ref>
<ref id="bibr15-0300060513477264"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Christopher</surname><given-names>K</given-names></name><name><surname>Finn</surname><given-names>PW</given-names></name><etal/></person-group>. <article-title>Graft produced interleukin-6 functions as a danger signal and promotes rejection after transplantation</article-title>. <source>Transplantation</source> <year>2007</year>; <volume>84</volume>: <fpage>771</fpage>–<lpage>777</lpage>.</citation></ref>
<ref id="bibr16-0300060513477264"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karimi</surname><given-names>MH</given-names></name><name><surname>Daneshmandi</surname><given-names>S</given-names></name><name><surname>Pourfathollah</surname><given-names>AA</given-names></name><etal/></person-group>. <article-title>Association of IL-6 promoter and IFN-γ gene polymorphisms with acute rejection of liver transplantation</article-title>. <source>Mol Biol Rep</source> <year>2011</year>; <volume>38</volume>: <fpage>4437</fpage>–<lpage>4443</lpage>.</citation></ref>
<ref id="bibr17-0300060513477264"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>schema for grading liver allograft rejection</surname><given-names>Banff</given-names></name></person-group>. <article-title>an international consensus document</article-title>. <source>Hepatology</source> <year>1997</year>; <volume>25</volume>: <fpage>658</fpage>–<lpage>663</lpage>.</citation></ref>
<ref id="bibr18-0300060513477264"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamath</surname><given-names>PS</given-names></name><name><surname>Kim</surname><given-names>WR</given-names></name></person-group>. <article-title>The model for end-stage liver disease (MELD)</article-title>. <source>Hepatology</source> <year>2007</year>; <volume>45</volume>: <fpage>797</fpage>–<lpage>805</lpage>.</citation></ref>
<ref id="bibr19-0300060513477264"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>WL</given-names></name><name><surname>Yao</surname><given-names>MY</given-names></name><etal/></person-group>. <article-title>Polymorphisms in cytokine genes and their association with acute rejection and recurrence of hepatitis B in Chinese liver transplant recipients</article-title>. <source>Arch Med Res</source> <year>2008</year>; <volume>39</volume>: <fpage>420</fpage>–<lpage>428</lpage>.</citation></ref>
<ref id="bibr20-0300060513477264"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>Z</given-names></name><name><surname>Gauldie</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses</article-title>. <source>J Clin Invest</source> <year>1998</year>; <volume>101</volume>: <fpage>311</fpage>–<lpage>320</lpage>.</citation></ref>
<ref id="bibr21-0300060513477264"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mihara</surname><given-names>M</given-names></name><name><surname>Hashizume</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>IL-6/IL-6 receptor system and its role in physiological and pathological conditions</article-title>. <source>Clin Sci (Lond)</source> <year>2012</year>; <volume>122</volume>: <fpage>143</fpage>–<lpage>159</lpage>.</citation></ref>
<ref id="bibr22-0300060513477264"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Turner</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis</article-title>. <source>Eur J Immunol</source> <year>1988</year>; <volume>18</volume>: <fpage>1797</fpage>–<lpage>1801</lpage>.</citation></ref>
<ref id="bibr23-0300060513477264"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kutukculer</surname><given-names>N</given-names></name><name><surname>Clark</surname><given-names>K</given-names></name><name><surname>Rigg</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>The value of posttransplant monitoring of interleukin (IL)-2, IL-3, IL-4, IL-6, IL-8, and soluble CD23 in the plasma of renal allograft recipients</article-title>. <source>Transplantation</source> <year>1995</year>; <volume>59</volume>: <fpage>333</fpage>–<lpage>340</lpage>.</citation></ref>
<ref id="bibr24-0300060513477264"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorczynski</surname><given-names>RM</given-names></name><name><surname>Adams</surname><given-names>RB</given-names></name><name><surname>Levy</surname><given-names>GA</given-names></name><etal/></person-group>. <article-title>Correlation of peripheral blood lymphocyte and intragraft cytokine mRNA expression with rejection in orthotopic liver transplantation</article-title>. <source>Surgery</source> <year>1996</year>; <volume>120</volume>: <fpage>496</fpage>–<lpage>502</lpage>.</citation></ref>
<ref id="bibr25-0300060513477264"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boros</surname><given-names>P</given-names></name><name><surname>Suehiro</surname><given-names>T</given-names></name><name><surname>Curtiss</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Differential contribution of graft and recipient to perioperative TNF-alpha, IL-1 beta, IL-6 and IL-8 levels and correlation with early graft function in clinical liver transplantation</article-title>. <source>Clin Transplant</source> <year>1997</year>; <volume>11</volume>: <fpage>588</fpage>–<lpage>592</lpage>.</citation></ref>
<ref id="bibr26-0300060513477264"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fishman</surname><given-names>D</given-names></name><name><surname>Faulds</surname><given-names>G</given-names></name><name><surname>Jeffery</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis</article-title>. <source>J Clin Invest</source> <year>1998</year>; <volume>102</volume>: <fpage>1369</fpage>–<lpage>1376</lpage>.</citation></ref>
<ref id="bibr27-0300060513477264"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brull</surname><given-names>DJ</given-names></name><name><surname>Montgomery</surname><given-names>HE</given-names></name><name><surname>Sanders</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Interleukin-6 gene -174G &gt;C and -572G &gt;C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2001</year>; <volume>21</volume>: <fpage>1458</fpage>–<lpage>1463</lpage>.</citation></ref>
<ref id="bibr28-0300060513477264"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Illig</surname><given-names>T</given-names></name><name><surname>Bongardt</surname><given-names>F</given-names></name><name><surname>Schöpfer</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source> <year>2004</year>; <volume>89</volume>: <fpage>5053</fpage>–<lpage>5058</lpage>.</citation></ref>
<ref id="bibr29-0300060513477264"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kocierz</surname><given-names>M</given-names></name><name><surname>Siekiera</surname><given-names>U</given-names></name><name><surname>Kolonko</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>-174G/C interleukin-6 gene polymorphism and the risk of transplanted kidney failure or graft loss during a 5-year follow-up period</article-title>. <source>Tissue Antigens</source> <year>2011</year>; <volume>77</volume>: <fpage>283</fpage>–<lpage>290</lpage>.</citation></ref>
<ref id="bibr30-0300060513477264"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Canossi</surname><given-names>A</given-names></name><name><surname>Piazza</surname><given-names>A</given-names></name><name><surname>Poggi</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Renal allograft immune response is influenced by patient and donor cytokine genotypes</article-title>. <source>Transplant Proc</source> <year>2007</year>; <volume>39</volume>: <fpage>1805</fpage>–<lpage>1812</lpage>.</citation></ref>
<ref id="bibr31-0300060513477264"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cartwright</surname><given-names>NH</given-names></name><name><surname>Keen</surname><given-names>LJ</given-names></name><name><surname>Demaine</surname><given-names>AG</given-names></name><etal/></person-group>. <article-title>A study of cytokine gene polymorphisms and protein secretion in renal transplantation</article-title>. <source>Transpl Immunol</source> <year>2001</year>; <volume>8</volume>: <fpage>237</fpage>–<lpage>244</lpage>.</citation></ref>
<ref id="bibr32-0300060513477264"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valdes</surname><given-names>AM</given-names></name><name><surname>Arden</surname><given-names>NK</given-names></name><name><surname>Tamm</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A meta-analysis of interleukin-6 promoter polymorphisms on risk of hip and knee osteoarthritis</article-title>. <source>Osteoarthritis Cartilage</source> <year>2010</year>; <volume>18</volume>: <fpage>699</fpage>–<lpage>704</lpage>.</citation></ref>
<ref id="bibr33-0300060513477264"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kämäräinen</surname><given-names>OP</given-names></name><name><surname>Solovieva</surname><given-names>S</given-names></name><name><surname>Vehmas</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Common <italic>interleukin-6</italic> promoter variants associate with the more severe forms of distal interphalangeal osteoarthritis</article-title>. <source>Arthritis Res Ther</source> <year>2008</year>; <volume>10</volume>: <fpage>R21</fpage>–<lpage>R21</lpage>.</citation></ref>
<ref id="bibr34-0300060513477264"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Du</surname><given-names>DY</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Identification of interleukin-6 promoter polymorphisms in the Chinese Han population and their functional significance</article-title>. <source>Crit Care Med</source> <year>2008</year>; <volume>36</volume>: <fpage>1437</fpage>–<lpage>1443</lpage>.</citation></ref>
<ref id="bibr35-0300060513477264"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>MY</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Interleukin-6 polymorphisms modify the risk of periodontitis: a systematic review and meta-analysis</article-title>. <source>J Zhejiang Univ Sci B</source> <year>2009</year>; <volume>10</volume>: <fpage>920</fpage>–<lpage>927</lpage>.</citation></ref>
<ref id="bibr36-0300060513477264"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name></person-group>. <article-title>The <italic>interleukin-6</italic> gene -572C/G promoter polymorphism modifies Alzheimer's risk in <italic>APOE</italic> ε4 carriers</article-title>. <source>Neurosci Lett</source> <year>2010</year>; <volume>482</volume>: <fpage>260</fpage>–<lpage>263</lpage>.</citation></ref>
<ref id="bibr37-0300060513477264"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Hodge</surname><given-names>DR</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Co-operative functions between nuclear factors NFκB and CCAT/enhancer-binding protein-β (C/EBP-β) regulate the IL-6 promoter in autocrine human prostate cancer cells</article-title>. <source>Prostate</source> <year>2004</year>; <volume>61</volume>: <fpage>354</fpage>–<lpage>370</lpage>.</citation></ref>
</ref-list>
</back>
</article>